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Edited by Veli-Pekka LehtoAbstract Tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL) speciﬁcally induces apoptosis in tumor cells but
may be toxic to human hepatocytes. Although hepatocytes are
susceptible to apoptotic signals mediated by TRAIL-receptor 2
(TRAIL-R2), we previously reported that some anti-TRAIL-
R2 monoclonal antibodies (mAbs) produce little hepatocyte tox-
icity. Those mAbs neutralized the cytotoxic activity of TRAIL
by inhibiting receptor–ligand binding. The hepatocyte-toxic
mAbs did not compete with TRAIL for binding to TRAIL-R2,
and potentiated ligand activity in both cancer cells and hepato-
cytes. A neutralizing antibody to TRAIL inhibited hepatocyte
death by anti-TRAIL-R2 mAbs, suggesting that the toxicity
may reﬂect their ability to potentiate membrane-bound TRAIL
on hepatocytes.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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antibody1. Introduction
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of TNF superfamily and activates two
distinct receptors [1]; TRAIL-R1 (DR4) and TRAIL-R2
(DR5) contain cytoplasmic death domains that can mediate
apoptosis. Soluble TRAIL (sTRAIL) potently induces apopto-
sis in various cancer cell lines, but spares most normal cell
types in vitro [2,3]. Furthermore, TRAIL exhibits anti-tumor
activity in mice xenograft models of human cancers although
in non-human primates its administration produces little toxic-
ity [2–4]. However, sTRAIL has been reported to induce hepa-
tocyte toxicity, which has raised concern about its safety as a
cancer therapy [5]. In mice, membrane-bound TRAIL trans-
duced by adenoviral systems produced hepatitis [6], indicating
that overexpression of membrane-bound TRAIL can mediate
apoptosis in normal murine liver cells. In addition, high-level
TRAIL expression is eﬀective in killing human hepatocytes
in vitro [7]. Although considerable controversy surrounds theAbbreviations: TNF, tumor necrosis factor; TRAIL, TNF-related ap-
optosis-inducing ligand; sTRAIL, soluble TRAIL; TRAIL-R, TRAIL
receptor; TRAIL-R2, TRAIL receptor 2; mAb, monoclonal antibody
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doi:10.1016/j.febslet.2005.09.009potential hepatocyte toxicity of sTRAIL [8], these observations
present the possibility that TRAIL may trigger the apoptosis
of normal human liver cells in vivo.
To examine the role of TRAIL receptors (TRAIL-Rs) in sig-
naling tumor apoptosis and hepatocyte toxicity, we generated
fully human monoclonal antibodies (mAbs) speciﬁc to
TRAIL-R1 and TRAIL-R2 using KM mice [9]. Antibodies
to TRAIL-R1 and TRAIL-R2 induced apoptosis in several
human cancer cell types, indicating that the mAbs mimic the
action of the natural ligand. We also reported that both
TRAIL-R1 and TRAIL-R2 mediated death signals in human
hepatocytes. All of the mAbs to TRAIL-R1 induced signiﬁcant
hepatocyte death, whereas the mAbs to TRAIL-R2 could be
separated into two groups, one with and the other without
severe hepatocyte toxicity [9].
We here report that certain mAbs to TRAIL-R2, which ex-
hibit little toxicity towards hepatocytes, are eﬃcient inhibitors
of TRAIL-induced apoptosis, whereas other anti-TRAIL-R2
mAbs, which induce hepatocyte death, enhance the activity
of sTRAIL in both cancer cells and human hepatocytes. Fur-
thermore, hepatocyte toxicity by this latter group of mAbs is
partially inhibited by a neutralizing antibody to TRAIL.2. Materials and methods
2.1. Cell lines
Colo205 (colorectal adenocarcinoma) and HepG2 (hepatoma) cell
lines were obtained from the American Type Culture Collection
(ATCC, Rockville, MD). Colo205 was maintained in RPMI1640 sup-
plemented with 10% fetal bovine serum and streptomycin. HepG2 was
maintained in minimum essential medium supplemented with 10% fe-
tal bovine serum, 1.0 mM sodium pyruvate and 0.1 mM non-essential
amino acids.
2.2. Reagents
The sTRAIL was purchased form R&D systems (Minneapolis,
MN). The preparation is supplied as non-tagged protein but it aﬀects
hepatocyte viability such as his-tagged one (unpublished data), which
may be due to inappropriate Zn content. Anti-TRAIL neutralizing
mAb, RIK-2, was purchased from eBioscience (San Diego, CA).
Anti-Fas agonistic mAb, CH-11, was purchased from MBL (Nagoya,
Japan). Fully human mAbs to TRAIL-R2 were generated using KM
mice as previously described [9].
2.3. Surface plasmon resonance analysis
Binding experiments were performed at 25 C using a Biacore 3000
(Biacore K.K., Tokyo, Japan). Anti-TRAIL-R2 mAbs were coupled to
CM5 sensor chip (Biacore K.K.) surface at a level of about 6000 res-
onance units using the amine coupling kit (Biacore K.K.). Injection
of 60 ll of recombinant sTRAIL-R2 proteins fused to human IgG
Fc portion at 9 lg/ml into the ﬂow cells was followed by 60 ll of
sTRAIL at 1 lg/ml, both at a ﬂow rate of 20 ll/min.ation of European Biochemical Societies.
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Fig. 1. Binding activity of mAbs to TRAIL-R2 against TRAIL-R2
with TRAIL. Anti-TRAIL-R2 mAbs, E11, L30, H48 and F4 were
coupled to CM5 sensor chip surface. Recombinant sTRAIL-R2
proteins were injected into the ﬂow cells, and the amount of TRAIL-
R2 that bound to immobilized mAbs to TRAIL-R2 was normalized as
100 RU. sTRAIL was injected at time 0.
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Cancer cells were cultured in 96-well plates (1 · 104 cells/well) and
exposed to the indicated concentrations of mAbs to TRAIL-R2. For
combined analysis with sTRAIL, subsequently sTRAIL was added
and incubated for 48 h at 37 C. Cell viability was determined using
the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI).
2.5. Human hepatocytes
Human hepatocytes have been described previously [9]. Hepatocytes
were cultured in CM5300 (CEDRA, Austin, TX) containing mAbs to
TRAIL-R2 in the presence of anti-human IgG (10 lg/ml) with or with-
out RIK-2 (1 lg/ml), for 8 h. For combined analysis with sTRAIL or
CH-11, hepatocytes were incubated in CM5300 containing the indi-
cated concentrations of sTRAIL or CH-11 and mAbs to TRAIL-R2
in the absence of goat anti-human IgG for 24 h. Hepatocyte viability
was determined using the CytoTox 96 Non-Radioactive Cytotoxic
Assay (Promega).
2.6. Statistics
All data are expressed as mean ± S.D. Diﬀerences between experi-
mental and control groups were determined using the Mann–Whitney
U test. Values of P < 0.05 were considered signiﬁcant.3. Results
3.1. Anti-TRAIL-R2 mAbs diﬀer in the inhibition of receptor–
ligand binding
We investigated the binding characteristics of TRAIL-R2 to
anti-TRAIL-R2 mAbs and sTRAIL by surface plasmon reso-
nance analysis. sTRAIL did not bind to E11 and L30-bound
TRAIL-R2 (Fig. 1), indicating that E11 and L30 compete with
sTRAIL for binding to TRAIL-R2. By contrast, sTRAIL was
able to bind to H48 and F4-bound TRAIL-R2 (Fig. 1), sug-
gesting that TRAIL-R2 binding region of H48 and F4 is diﬀer-
ent from that of sTRAIL. This result demonstrates that mAbs
to TRAIL-R2 are diﬀerent in the blocking of TRAIL-R2–
sTRAIL interaction.E11
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Fig. 2. Induction of cancer cell death by cross-linked mAbs to TRAIL-R2. C
E11, L30, H48 and F4 in the presence (j) or absence (h) of anti-human Ig3.2. Cytotoxic activity of sTRAIL is modulated by mAbs to
TRAIL-R2 in cancer cells
We treated Colo205 cells with the mAbs to TRAIL-R2 and
sTRAIL to investigate the eﬀect of the mAbs to TRAIL-R2 on
TRAIL activity. Because all of the mAbs to TRAIL-R2 exhib-
ited potent cytotoxic activity in Colo205 cells upon cross-link-
ing (Fig. 2), mAb treatment was performed in the absence of
anti-human IgG. The mAbs E11 and L30 blocked TRAIL-
induced death of Colo205 cells in a dose-dependent manner.
On the contrary, H48 and F4 dose-dependently enhanced the
apoptosis-inducing activity of the ligand (Fig. 3A). We also
tested the activity of mAbs co-incubated with sTRAIL in hep-
atoma HepG2 cells (Fig. 3B), which were relatively resistant to
TRAIL (Fig. 3A, B), and obtained the result similar to that in
Colo205 cells. Moreover, E11 and L30 inhibited eﬀector cas-
pase activation by TRAIL whereas H48 and F4 augmentedF4
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olo205 cells were incubated with the indicated concentrations of mAbs,
G for 48 h. Cell viability was determined as described in Section 2.
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Fig. 3. Modulation of TRAIL activity by mAbs to TRAIL-R2 in cancer cells. Cancer cells (Colo205 (A), HepG2 (B)) were incubated with both
sTRAIL (1 ng/ml, 10 ng/ml, respectively) and the indicated concentrations of mAbs, E11, L30, H48 and F4 for 48 h. Cell viability was determined as
described in Section 2. Data are expressed as means ± S.D., \P < 0.05 compared with no antibody addition.
E. Mori et al. / FEBS Letters 579 (2005) 5379–5384 5381its activation in both cell lines (data not shown). These results
indicate that E11 and L30 neutralize the activity of TRAIL
while H48 and F4 potentiate its ligand activity in both
TRAIL-sensitive and TRAIL-resistant cancer cells.
3.3. Eﬀect of TRAIL activity on hepatocyte toxicity induced by
mAbs to TRAIL-R2
H48 and F4, the hepatocyte-toxic TRAIL-R2 mAbs, signif-
icantly enhanced the activity of TRAIL in cancer cells. Next,
we examined the activity of the mAbs to TRAIL-R2 withTRAIL in human hepatocytes. Hepatocytes were treated
simultaneously with anti-TRAIL-R2 mAbs and sTRAIL in
the absence of anti-human IgG. E11 and L30 inhibited
TRAIL-induced hepatocyte death (Fig. 4A). By contrast, both
H48 and F4 augmented the eﬀect of a non-toxic dose of
TRAIL in hepatocyte cultures (Fig. 4A). No mAbs to
TRAIL-R2 aﬀected the hepatocyte death-inducing activity of
anti-Fas agonistic antibody CH-11 (Fig. 4B), indicating that
the observed eﬀect of anti-TRAIL-R2 mAbs was speciﬁc to
TRAIL. These results suggested to us that the toxicity of these
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Fig. 4. Potentiation of cytotoxic activity of TRAIL by mAbs to TRAIL-R2 in human hepatocytes. Human hepatocytes were incubated with
sTRAIL at 1 ng/ml (H48 and F4) or 3 ng/ml (E11 and L30) (A) or mAb to Fas (CH-11) at 1000 ng/ml (B) and mAbs, E11, L30, H48 and F4 at
1000 ng/ml for 24 h. Cell viability was determined as described in Section 2. Data are expressed as means ± S.D., \P < 0.05 compared with sTRAIL,
CH-11 or mAb addition.
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ment of endogenous membrane-anchored TRAIL activity on
hepatocytes. Indeed, mRNA for TRAIL was detected in cul-
tured hepatocytes by RT-PCR (data not shown).
To test this idea, a neutralizing mAb to TRAIL was included
with the hepatocyte-toxic anti-TRAIL-R2 mAbs in the hepa-
tocyte cultures. Hepatocytes were pretreated with the mAb
speciﬁc to the ligand (RIK-2), which can neutralize the apop-
tosis-inducing activity of membrane-bound TRAIL, and cul-
tured with mAbs to TRAIL-R2, H48 and F4, upon cross-
linking. RIK-2 completely reduced the toxicity induced byH48 and partially aﬀected F4 (Fig. 5). These observations sug-
gest that the toxicity induced by some mAbs to TRAIL-R2
may be, at least in part, due to the potentiation of endogenous
hepatocyte TRAIL activity.4. Discussion
A number of antibodies to TNF receptor superfamily mem-
bers, such as TNFR, Fas and CD40, have been developed.
Some antibodies have activities similar to the natural ligands,
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Fig. 5. Eﬀect of neutralizing TRAIL mAb on hepatocyte toxicity induced by mAb to TRAIL-R2. Human hepatocytes were incubated with (j) or
without mAb to TRAIL (RIK-2) (h) and the indicated concentrations of mAbs, H48 and F4 in the presence of anti-human IgG for 8 h. Cell viability
was determined as described in Section 2. Data are expressed as means ± S.D., \P < 0.05 compared with no addition of mAb to TRAIL.
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CD40 antibodies have been investigated and some of these
were classiﬁed as agonistic or antagonistic [10,11]. S2C6/
SGN-14, one of the mAbs to CD40, shows agonistic activity
and stimulates B cell proliferation [10]. Furthermore, S2C6/
SGN-14 can also potentiate CD40 ligand activity when used
in combination with the ligand [10]. On the contrary, 5D12,
another antibody to CD40, has antagonistic activity [11].
5D12 blocks the CD40 ligand-CD40 pathway and is devoid
of CD40 stimulatory activity. In this study, we demonstrated
that four mAbs to TRAIL-R2, E11, F4, H48 and L30, can
be classiﬁed as ligand blocker or ligand potentiator when ap-
plied in the absence of cross-linking reagents. E11 and L30
blocked sTRAIL activity, indicating that these mAbs antago-
nize the TRAIL–TRAIL-R2 signal. On the contrary, H48
and F4 enhanced TRAIL activity in the presence of the ligand,
suggesting that these mAbs are similar to S2C6/SGN-14
regarding the ability to augment ligand activity. Since all of
our mAbs to TRAIL-R2 showed apoptosis-inducing activity
in cancer cells upon cross-linking [9], cross-linking of anti-
TRAIL-Rs mAbs is thought to cause oligomerization of
TRAIL-Rs to an extent that is suﬃcient to induce cell death
independent of the ligand and characteristics of mAbs [12].
Ligand potentiation activity of mAb appears to be responsi-
ble for anti-tumor activity in CD40 because S2C6/SGN-14 en-
hances an inhibitory activity against proliferation of cancer
cells in the presence of CD40L-expressing cells [10]. Very same
activity induces not only tumor cell death but hepatocyte tox-
icity in TRAIL-R2. As we showed in this study, H48 and F4
enhanced soluble ligand activity and induced cell death of both
tumor cells and hepatocytes. In addition, hepatocyte death in-
duced by these mAbs was inhibited by a neutralizing antibody
to TRAIL. Surface plasmon resonance analysis revealed that
more sTRAIL was able to bind F4-bound TRAIL-R2 than
H48-bound TRAIL-R2. This may explain the results that F4
exhibited stronger ligand potentiation activity than H48 and
that neutralization of endogenous TRAIL activity reduced
hepatocyte toxicity induced by H48 completely, but partially
by F4. These observations demonstrate that hepatocytes ex-
press both TRAIL and TRAIL-R2 and that the toxicity by
H48 and F4 might be due to potentiation of TRAIL on hepa-
tocytes. Therefore, expression level of TRAIL and TRAIL-Rs,
particularly in liver, should be considered for clinical applica-
tion of TRAIL signaling. It has been reported that viral infec-
tion induces an increase in TRAIL expression [13–15].
Speciﬁcally, in hepatitis B virus and human immunodeﬁciencyvirus-infected patients, the expression levels of sTRAIL were
higher than those of healthy donors, in peripheral blood and
serum samples [13,14]. High expression of TRAIL was also de-
tected in livers of patients with chronic hepatitis C and hepati-
tis B-mediated acute liver failure, indicating that the expression
level of TRAIL diﬀers between healthy people and those with
viral infection [15]. Notably, viral infection results in overex-
pression of TRAIL in liver, whereas upregulation of TRAIL-
Rs is detected in incidences of hepatitis B and C infection
[15,16]. Thus, potentiation of TRAIL expressed on hepato-
cytes may induce a bystander eﬀect and increase the risk of
liver injury in virus-infected patients.
More recently, it was reported that TRAIL-expressing liver
NK cells are cytotoxic to self-hepatocytes in mice [17]. Even un-
der naı¨ve conditions, approximately 30–40% of NK cells consti-
tutively express TRAIL. Moreover, the observation that the
hepatocyte toxicity mediated by these cells is partially inhibited
by a neutralizing TRAIL mAb, demonstrates conclusively that
TRAIL on liver NK cells contributes to hepatocyte toxicity.
Although possible diﬀerences between rodent models and pri-
mates should be considered, it is clear that administration of
agents that potentiate ligand activity might lead not only to
enhancement of endogenous TRAIL activity on hepatocytes,
but also to augmentation of NK cell TRAIL function, thereby
inducing hepatocyte death as well as tumor cell apoptosis.
Taken together, our results further elucidate mechanisms of
hepatocyte toxicity induced by mAbs to TRAIL-R2 and high-
light the importance of selecting mAbs for cancer therapy.
Anti-TRAIL-R2 mAbs that antagonize TRAIL binding but
do not enhance the activity of endogenous TRAIL should theo-
retically be safe as anti-cancer therapies, but the therapeutic use
of these mAbs should be circumspect because they induced rel-
atively weak toxicity in hepatocytes when strongly cross-linked
in vitro [9]. Although the expression level of membrane-bound
TRAIL,whichmay diﬀer among patients, should be considered,
mAbs to TRAIL-R2 that potentiate the ligand activity might be
candidates for the treatment of TRAIL-resistant tumors.
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